Surgery for ovarian cancer that returns after platinum treatment
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether a second surgery to remove all visible cancer can help people with ovarian cancer that came back within 6 months of finishing platinum chemotherapy. The goal is to see if this surgery improves outcomes compared with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that has come back after up to 3 previous treatments.
- Your cancer returned within 6 months after your last platinum-based chemotherapy.
- Your first surgery was able to remove all visible cancer (called R0).
- A PET-CT scan shows that your cancer is only in the belly area, with no more than 5 separate spots, and you have less than 500 ml of fluid in your belly (ascites).
- You are generally well (able to do daily activities) and your blood counts, kidney, and liver function are within acceptable ranges.
- You have not had radiation to the belly or pelvis, and you do not have other cancers that are not fully treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
This trial tests if a second surgery to remove tumors, followed by heated chemotherapy in the abdomen, helps people with ovarian, fallopian tube, or peritoneal cancer whose cancer has returned while taking PARP inhibitor drugs.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
This trial tests whether removing recurrent ovarian cancer with surgery after chemotherapy can help patients live longer. It is for women whose cancer came back at least 6 months after finishing platinum-based chemo and who responded to chemo after the recurrence.
Hear when a new Cytoreductive Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.